Correction to: Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS) [0.03%]
托法替布治疗类风湿关节炎的疗效和安全性的meta分析及GRADE评估
Anne Quinquenel,Stéphane Leprêtre,Marie Sarah Dilhuydy et al.
Anne Quinquenel et al.
Published Erratum
Annals of hematology. 2025 Oct 13. DOI:10.1007/s00277-025-06632-3 2025
Ying Liu,Yanna Zhao
Ying Liu
Wolfgang Füreder,Sonja Granser,Andreas Repa et al.
Wolfgang Füreder et al.
Before complement inhibitors were available, pregnancy in women with paroxysmal nocturnal hemoglobinuria (PNH) was associated with considerable mortality, mainly due to thromboembolism. The complement-C5 inhibitor eculizumab has decreased t...
Safety and feasibility of intermediate-dose post-transplant cyclophosphamide for graft-versus-host disease prophylaxis [0.03%]
异基因造血干细胞移植后中剂量环磷酰胺作为移植物抗宿主病预防的安全性和可行性研究
Natasha Venugopal,Andrew McGowan,Yoshitaka Inoue et al.
Natasha Venugopal et al.
Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first line regimens: A multicentric Italian experience [0.03%]
意大利多中心经验：抗CD38单克隆抗体为基础的一线方案治疗的新诊断多发性骨髓瘤患者感染事件
Angela Rago,Francesca Fioritoni,Carmine Liberatore et al.
Angela Rago et al.
Multiple myeloma (MM) is a malignancy characterized by the clonal proliferation of plasma cells. It accounts for approximately 1% of all cancers and is the second most common hematologic malignancy after lymphoma. Infections represent a maj...
Global burden of acute lymphoblastic leukemia following the COVID-19 pandemic [0.03%]
2019冠状病毒病大流行后的急性淋巴细胞白血病疾病负担
Hongxuan Fan,Yafen Yang,Yanyan Lu et al.
Hongxuan Fan et al.
Objective: ALL is the most common childhood cancer globally, accounting for about 25% of cancer diagnoses in children under 15 years old. This study aimed to investigate the temporal trends and disparities in the global b...
Real-world outcomes and prognostic factors in primary mediastinal B-cell lymphoma: a multicenter study of 157 patients [0.03%]
原发纵隔B细胞淋巴瘤的临床特点和预后因素分析：157例患者的多中心研究
Selin Küçükyurt,Oguzhan Koca,Esra Terzi Demirsoy et al.
Selin Küçükyurt et al.
Primary mediastinal B-cell lymphoma (PMBCL) is a rare and distinct subtype of non-Hodgkin lymphoma. No consensus exists on optimal frontline treatment, and the use of R-CHOP ± radiotherapy (RT) and DA-EPOCH-R ± RT remains common, yet comp...
Haemoglobin variants in nigeria: real-world data from a point-of-care device [0.03%]
尼日利亚的血红蛋白变异类型：来自即时医疗设备的真实世界数据
Taiwo Kotila,Oladapo Aworanti,Chima Akunwata et al.
Taiwo Kotila et al.
Low-middle-income countries (LMICs) have used cellulose acetate electrophoresis preferentially in the diagnosis of haemoglobinopathies. Recently, point-of-care (POC) devices have made the diagnosis faster and cheaper. This study analyzed re...
A multicenter study on the prognostic value of prednisone response in pediatric acute lymphoblastic leukemia [0.03%]
一项关于泼尼松反应对儿童急性淋巴细胞白血病预后价值的多中心研究
Jia-Tong Dai,Yun-Yan He,Ya-Ting Zhang et al.
Jia-Tong Dai et al.
Background: Prednisone response (PR) remains a key early treatment indicator in pediatric acute lymphoblastic leukemia (ALL). However, its independent prognostic significance has waned with the advent of minimal residual ...
Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib [0.03%]
新诊断的费城染色体阳性急性淋巴细胞白血病患者使用ponatinib或imatinib治疗后的临床反应和治疗耐受性对HRQoL的影响
Ajibade Ashaye,Ling Shi,Ibrahim Aldoss et al.
Ajibade Ashaye et al.
In the phase 3 PhALLCON trial (NCT03589326), ponatinib demonstrated superior efficacy, patient-reported treatment tolerability, and health-related quality of life (HRQoL) compared to imatinib in adults with newly diagnosed Philadelphia chro...